News - Merck & Co

Filter

Current filters:

Merck & Co

Popular Filters

36 to 60 of 283 results

New Zealand views access to sugammadex and atomoxetine and baclofen injection funding

02-12-2013

New Zealand’s Pharmaceutical Management Agency PHARMAC is seeking feedback on the following proposals…

Asia-PacificBridionEli LillyLioresal IntrathecalMerck & CoNeurologicalNew ZealandPharmaceuticalRegulationStrattera

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

Strong one-year results in patients with advanced melanoma treated with Merck’s MK-3475

19-11-2013

US pharma giant Merck & Co has announced additional data for MK-3475, an investigational anti-PD-1 immunotherapy,…

Merck & CoMK-3475OncologyPharmaceuticalResearch

Pharma figures high in EU R&D Investment Scoreboard, but led by US firms

19-11-2013

Though not topping the league table, the pharmaceutical industry had a number of drugmakers among the…

EuropeFinancialGlaxoSmithKlineJohnson & JohnsonMerck & CoNorth AmericaNovartisPfizerPharmaceuticalResearchRocheSanofi

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

Akorn shells out $52.8 million for rights to three Merck drugs

Akorn shells out $52.8 million for rights to three Merck drugs

18-11-2013

USA-based niche generic drugmaker Akorn has acquired from pharma giant Merck & Co the US rights to three…

AkornAzaSiteCosoptGenericsMerck & CoMergers & AcquisitionsNorth AmericaOphthalmics

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

Merck’s investigational Timothy grass allergy tablet reduced symptoms in Phase III study

12-11-2013

US pharma giant Merck & Co (NYSE: MRK) has published positive results for its investigational Timothy…

ALK AbelloGrazaxImmunologicalsMerck & CoNorth AmericaPharmaceuticalResearchUSA

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

Merck & Co’s investigational HPV vaccine shows broader efficacy than Gardasil

Merck & Co’s investigational HPV vaccine shows broader efficacy than Gardasil

04-11-2013

Merck & Co has revealed an overview of its clinical trial program for V503, its investigational nine-valent…

GardasilMerck & CoNorth AmericaPharmaceuticalResearchVaccines

Merck & Co sales and earnings fall, but latter still beat expectations

Merck & Co sales and earnings fall, but latter still beat expectations

29-10-2013

US pharma giant Merck & Co posted third-quarter 2013 financial results, with declines in both sales and…

FinancialMerck & CoPharmaceutical

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

Merck & Co expects to file BLA for HPV vaccine candidate V503 this year

25-10-2013

Merck & Co yesterday provided an overview of the clinical trial program for V503, the company’s investigational…

Merck & CoNorth AmericaPharmaceuticalRegulationResearchV503Vaccines

FDA grants Merck’s hepatitis C treatment breakthrough designation

FDA grants Merck’s hepatitis C treatment breakthrough designation

23-10-2013

US pharma giant Merck & Co has announced that the US Food and Drug Administration has granted MK-5172/MK-8742…

Anti-viralsMerck & CoNorth AmericaPharmaceuticalRegulation

Sanofi Pasteur MSD first vaccine company in pilot for rapid European HTA

17-10-2013

Sanofi Pasteur MSD, a vaccines joint venture between drug major Sanofi of France’s Sanofi Pasteur…

Merck & CoPharmaceuticalRegulationSanofiSanofi Pasteur MSDVaccinesZostavax

New data on Merck and Endocyte’s vintafolide in ovarian cancer

New data on Merck and Endocyte’s vintafolide in ovarian cancer

15-10-2013

Merck & Co and partner Endocyte today announced the on-line publication of results from the randomized…

EndocyteMerck & CoOncologyPharmaceuticalResearchvintafolide

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

Merck & Co joins string of “restructurers,” cutting 8,500 jobs

Merck & Co joins string of “restructurers,” cutting 8,500 jobs

02-10-2013

US pharma giant Merck & Co is the latest of a flood of leading drugmakers to announce restructuring plans,…

FinancialManagementMerck & CoPharmaceuticalResearch

Aspen Pharma reports rise in profits from new product launches

11-09-2013

South Africa's leading drugmaker Aspen Pharmacare (APN: SJ) has released financial results which show…

ArixtraAspen PharmacareFinancialFraxiparineGlaxoSmithKlineMerck & CoPharmaceuticalRest of the World

AstraZeneca gains rights to Merck ovarian cancer candidate

11-09-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

First biosimilar monoclonal antibody approved in Europe

10-09-2013

US injectables and infusion technologies firm Hospira (NYSE: HSP) says the European Commission has approved…

Anti-Arthritics/RheumaticsBiotechnologyCellTrionEuropeGenericsHospiraInflectraMerck & CoRemicadeResearch

Depomed expands geographic scope of metformin deal with Merck

10-09-2013

USA-based Depomed (Nasdaq: DEPO) says it has expanded the geographic scope of its non-exclusive license…

DepomedDiabetesJanumetLicensingMerck & CometforminPharmaceutical

Merck & Co to co-promote diabetes agent ipragliflozin in Japan

02-09-2013

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a co-promotion agreement in Japan with…

Asia-PacificAstellas PharmaDiabetesipragliflozinKotobuki PharmaceuticalLicensingMarkets & MarketingMerck & CoPharmaceutical

BPH drug doesn't increase risk of death, but does save men from prostate cancer

15-08-2013

A long-term follow-up to a groundbreaking study led by the director of the Cancer Therapy & Research…

finasterideGenericsMen's HealthMerck & CoOncologyPharmaceuticalProscarResearch

Avanir to promote Merck's diabetes drug Januvia

13-08-2013

US drugmaker Avanir Pharmaceuticals (Nasdaq: AVNR) has entered into an exclusive agreement with US drug…

Avanir PharmaceuticalsDiabetesJanuviaMarkets & MarketingMerck & CoNorth AmericaPharmaceutical

36 to 60 of 283 results

Back to top